Peptidream Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Patrick Crawford Reid
- Full Time Employees
- 645
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 3-25-23 Tonomachi Kawasaki KN Japan 210-0821
- IPO Date
- Jun 11, 2013
- Website
- peptidream.com
- Similar Companies
- Business
- PeptiDream Inc. (4587.T), a public biopharmaceutical company founded in 2006 and headquartered in Kawasaki, Japan, engages in the discovery, development and commercialization of constrained peptides, small molecules and peptide-drug conjugate therapeutics; macrocyclic peptide-based therapeutics and diagnostics; peptide-drug conjugates including radioligand therapies and multi-functional peptide conjugates; and radiopharmaceutical and radio-diagnostic products. The company leverages its proprietary Peptide Discovery Platform System (PDPS) to generate non-standard peptide libraries for identifying potent, selective macrocyclic peptide candidates targeting oncology, immunology, metabolic disorders, neuromuscular conditions, infectious diseases and allergic indications, with a development pipeline featuring PD-L1 (Ph1), PD-L1 BMS-986229 (Ph1), CD38 BHV-1100 + NK cells for multiple myeloma (Ph1), GhR AZP-3813 for acromegaly/NET (Ph1), preclinical programs including Glypican-3 for liver cancer, Myostatin for DMD/muscle disorders, TfR for neuromuscular disorders, c-Kit for allergic conditions, c-Met and HA-protein for influenza. PeptiDream operates primarily through its Drug Discovery and Development segment via strategic research collaborations, technology licensing of PDPS and pipeline expansion with global pharmaceutical partners including Novartis, MSD (Merck), Genentech and Bristol Myers Squibb, serving therapeutic areas across oncology, central nervous system disorders and metabolic diseases with worldwide geographic reach. Recent developments include a 2024 expansion of its long-standing peptide discovery collaboration with Novartis granting exclusive global rights for radioligand therapy programs using PDPS-optimized macrocyclic peptides conjugated with radionuclides, featuring $180 million upfront payment and up to $2.7 billion in milestones plus royalties; ongoing multi-target partnerships such as with MSD for peptide drug conjugates; and pipeline advancements including multiple Phase 1 clinical programs.
Company News
PeptiDream (PPTDF) Expected to Announce Quarterly Earnings on Wednesday
PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis